This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spectrum Pharmaceuticals Launches A Broad-based FUSILEV® Marketing Campaign; Increases Sales Force Footprint

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, today announced the launch of the Company’s broad-based FUSILEV (levoleucovorin) marketing campaign directed towards oncologists, nurses, office practice managers and pharmacists. The recently launched campaign features a new website, health care professional educational tools and resources, digital and online campaign, and peer-to-peer live educational programs.

In conjunction with the launch of this new marketing campaign, and in an effort to further increase our market penetration, Spectrum has made the strategic decision to dedicate additional existing sales resources to FUSILEV. Augmenting the Company’s dedicated FUSILEV sales force, all ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use representatives will now also promote FUSILEV. This strategy will leverage all existing health care professional relationships and effectively increase Spectrum’s FUSILEV dedicated sales resources by approximately 50% with no significant increase in operating expenses.

“Physicians continue to increasingly use FUSILEV because of its purity, clinical profile, and supply reliability,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “Strong commercial support for FUSILEV has been rewarded by increased market penetration and sustained customer loyalty. We believe this campaign will continue to raise awareness of the FUSILEV brand as well as grow the folate analog market.”

About FUSILEV® (levoleucovorin)

FUSILEV, a folate analog, is approved as a ready-to-use solution (FUSILEV Injection), and as a freeze-dried powder (FUSILEV for Injection). FUSILEV is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. FUSILEV is also indicated for rescue after high-dose methotrexate therapy in osteosarcoma. FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. FUSILEV, under various trade names, is marketed outside the United States by Pfizer, Sanofi-Aventis, and Takeda.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,830.18 +39.99 0.24%
S&P 500 1,984.23 +4.31 0.22%
NASDAQ 4,753.0130 +4.6520 0.10%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs